111 (NASDAQ:YI) Receives “Sell (E+)” Rating from Weiss Ratings

Weiss Ratings restated their sell (e+) rating on shares of 111 (NASDAQ:YI) in a research note issued to investors on Tuesday,Weiss Ratings reports.

111 Trading Down 8.8 %

111 stock opened at $6.15 on Tuesday. The firm has a market capitalization of $52.59 million, a P/E ratio of -1.54 and a beta of 0.57. 111 has a twelve month low of $4.15 and a twelve month high of $14.10. The stock’s fifty day simple moving average is $8.22 and its 200-day simple moving average is $7.51.

111 (NASDAQ:YI) last issued its quarterly earnings results on Thursday, March 20th. The company reported ($0.04) earnings per share (EPS) for the quarter. The company had revenue of $527.14 million for the quarter.

Institutional Trading of 111

Several institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. raised its stake in 111 by 43,619.9% during the 4th quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company’s stock worth $191,000 after acquiring an additional 305,339 shares in the last quarter. Napean Trading & Investment Co Singapore PTE Ltd purchased a new position in shares of 111 during the fourth quarter worth about $245,000. Finally, FIL Ltd purchased a new position in shares of 111 during the fourth quarter worth about $450,000. Hedge funds and other institutional investors own 21.32% of the company’s stock.

About 111

111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.